• Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Contact Icon Contact Icon Contact Icon
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact

The Disease

WHO Group 1 : Pulmonary Arterial Hypertension (PAH)

PAH is a vascular disease of the pulmonary arteries that leads to a progressive narrowing of the blood vessels that provide blood flow from the right side of the heart to the lungs and results in an increase in pulmonary vascular resistance and pulmonary artery pressure.  The elevated pulmonary arterial pressure creates an excessive workload on the right side of the heart and is ultimately associated with heart failure and increased mortality.  Common symptoms of PAH include shortness of breath, reduced exercise capacity, fatigue, weakness, and syncope. There are both sporadic and inherited forms. Despite an improved ability to screen for PAH with echocardiography, it typically presents late in the disease state.

Pulmonary arterial hypertension (PAH) is a rare and progressive disorder characterized by abnormally high blood pressure in the pulmonary artery. It is classified as an orphan disease with an estimated prevalence of 15 to 50 persons per million within the United States.

Our Products
Education Center Publications
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Contact
    • Email

Tenax Therapeutics

A Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies.

Contact Icon Contact Icon Contact Icon

© Copyright 2025 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design

  • Privacy Policy
  • Terms of Service